Lexaria Bioscience -CW25LEXXWPreferred / convertible
13F holders, Q3 2025 (September 30)4holders +2
1new positions
0sold out
$0.06avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Lexaria Bioscience -CW25 (LEXXW) in their 13F filings, up 2 from Q2 2025. 1 opened new positions and 0 sold out. The largest holders were Heights Capital Management, Inc. ($3K), UBS Group AG ($194) and Clear Street Group Inc. ($8).
- Company
- Lexaria Bioscience -CW25
- CUSIP
- 52886N117
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 11,314 shares bought and 1,771 shares sold, net +9,543 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Heights Capital Management, Inc. | — | No change | 41,251 | $3K |
| UBS Group AG | — | Reduce -42.2% | 2,424 | $194 |
| Clear Street Group Inc. | — | — | 100 | $8 |
| HRT Financial LP | — | New | 11,314 | $0 |
"% of holder's portfolio" is LEXXW's weight in each manager's 13F, not the share of Lexaria Bioscience -CW25 the manager owns.